Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers

Journal of Acquired Immune Deficiency Syndromes : JAIDS
Rosa F YehA D Kashuba

Abstract

The effect of lopinavir/ritonavir (LPV/r) administration on cytochrome P450 (CYP) enzyme activity was quantified using a phenotyping biomarker cocktail. Changes in CYP2C9, CYP2C19, CYP3A, CYP1A2, N-acetyltransferase-2 (NAT-2), and xanthine oxidase (XO) activities were evaluated using warfarin (WARF) + vitamin K, omeprazole (OMP), intravenous (IV) and oral (PO) midazolam (MDZ), and caffeine (CAF). : Open-label, multiple-dose, pharmacokinetic study in healthy volunteers. Subjects (n = 14) simultaneously received PO WARF 10 mg, vitamin K 10 mg, OMP 40 mg, CAF 2 mg/kg, and IV MDZ 0.025 mg/kg on days (D) 1 and 14, and PO MDZ 5 mg on D2 and D15. LPV/r (400/100 mg twice daily) was administered on D4-17. CYP2C9 and CYP2C19 activities were quantified by S-WARF AUC0-inf and OMP/5-hydroxy OMP ratio, respectively. CYP1A2, NAT-2, and XO activities were quantified by urinary CAF metabolite ratios. Hepatic and intestinal + hepatic CYP3A activities were quantified by IV (CL) and PO (CL/F) MDZ clearance, respectively. After LPV/r therapy, CYP2C9, CYP2C19, and CYP1A2 activity increased by 29%, 100%, and 43% (P = 0.001, 0.046, and 0.001), respectively. No changes were seen in NAT-2 or XO activity. Hepatic and intestinal + hepatic CYP3A activity d...Continue Reading

References

Oct 1, 1992·Clinical Pharmacology and Therapeutics·U Breyer-PfaffP Baumann
Jun 1, 1995·Clinical Pharmacology and Therapeutics·J D BalianD A Flockhart
Aug 1, 1996·Clinical Pharmacology and Therapeutics·J S MarinacD A Flockhart
May 1, 1997·Antimicrobial Agents and Chemotherapy·A HsuJ M Leonard
Sep 5, 1998·Clinical Pharmacology and Therapeutics·J C GorskiS D Hall
Dec 3, 1998·Antimicrobial Agents and Chemotherapy·H L ShamD W Norbeck
Dec 23, 1998·British Journal of Clinical Pharmacology·N N VachharajaniD S Greene
Jan 7, 1999·The Annals of Pharmacotherapy·K R KnoellE S Cousins
Apr 23, 1999·Pharmaceutical Research·R B KimG R Wilkinson
May 8, 1999·British Journal of Clinical Pharmacology·D J FosterF Bochner
Oct 6, 1999·AIDS·G Newshan, P Tsang
Dec 3, 1999·Journal of Clinical Pharmacy and Therapeutics·E Tanaka
Mar 29, 2001·The New England Journal of Medicine·S C Piscitelli, K D Gallicano
Aug 29, 2001·Clinical Pharmacokinetics·H Takahashi, H Echizen
Mar 27, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Susan ClarkeDavid J Back
Jun 28, 2002·The Annals of Pharmacotherapy·Amanda H CorbettAngela D M Kashuba
Aug 13, 2002·Journal of Clinical Psychopharmacology·Scott R PenzakMichael W Jann
Aug 22, 2002·Clinical Pharmacology and Therapeutics·Myong-Jin KimAnne N Nafziger
Aug 22, 2002·Clinical Pharmacology and Therapeutics·Junji SaruwatariTakashi Ishizaki
Mar 4, 2003·Biological & Pharmaceutical Bulletin·Tomoko KitaKatsuhiko Okumura
Mar 19, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ajay MadanAndrew Parkinson
Mar 29, 2003·Drugs·Risto S Cvetkovic, Karen L Goa
May 2, 2003·The Journal of Pharmacy and Pharmacology·James L WeemhoffDavid J Greenblatt
Aug 7, 2003·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Robert C StevensRichard Bertz
Aug 9, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elinore F McCance-KatzPeter Jatlow
Aug 28, 2003·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Ashokkumar B JainJohn J Fung
Oct 31, 2003·AIDS Research and Human Retroviruses·Marta BoffitoGiovanni Di Perri
Mar 16, 2004·Pharmacogenomics·Takahisa FurutaTakashi Ishizaki
May 12, 2004·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Naser L RezkAngela D M Kashuba
Jul 13, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Michael L LimAngela D M Kashuba

❮ Previous
Next ❯

Citations

Jul 12, 2008·Archives of Toxicology·Olavi PelkonenHannu Raunio
Jun 30, 2009·European Journal of Clinical Pharmacology·Natascia CortiChristiane Pauli-Magnus
Aug 11, 2010·European Journal of Clinical Pharmacology·Tuija H NieminenKlaus T Olkkola
Nov 4, 2010·European Journal of Clinical Pharmacology·Dario CattaneoEmilio Clementi
Mar 2, 2011·Journal of Thrombosis and Thrombolysis·Edith NutescuErika Hellenbart
Feb 10, 2012·The Journal of Antimicrobial Chemotherapy·Pauline Byakika-KibwikaConcepta Merry
Aug 19, 2007·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Christine A HughesLilly J Miedzinski
Oct 26, 2013·Clinical Pharmacokinetics·Tony K L KiangMary H H Ensom
Aug 29, 2014·Clinical Pharmacokinetics·Kajal B LarsonEdward P Acosta
Jun 16, 2014·International Journal of Antimicrobial Agents·Birgit S JacobsDavid M Burger
Oct 29, 2013·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de expertos de GeSIDA y Plan Nacional sobre el Sida
Aug 5, 2015·Journal of Clinical Pharmacology·David J Greenblatt
Jun 18, 2010·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de Expertos de Gesida, UNKNOWN Plan Nacional sobre el Sida
Mar 8, 2016·The Journal of Antimicrobial Chemotherapy·Catia MarzoliniDavid Back
Sep 25, 2008·Journal of Clinical Pharmacology·Martin S Rhee, David J Greenblatt
Jul 20, 2007·The Journal of Pharmacy and Pharmacology·Michael D PerloffDavid J Greenblatt
Aug 21, 2012·Basic & Clinical Pharmacology & Toxicology·Virginie AncrenazJules Desmeules
Oct 10, 2014·British Journal of Clinical Pharmacology·Richard M HoglundJoel Tarning
Feb 27, 2015·European Journal of Clinical Investigation·Michele CorrealeDonato Lacedonia
Aug 21, 2014·Journal of Ethnopharmacology·Erica C LarsonMichael R Franklin
Jul 2, 2016·Neurotoxicity Research·Ankit ShahAnil Kumar
Sep 30, 2015·The American Journal of Tropical Medicine and Hygiene·Siwalee RattanapunyaKesara Na-Bangchang
Jun 19, 2018·The Annals of Pharmacotherapy·Patricia Pecora Fulco, Laura Hill Bannister
Oct 16, 2015·Antimicrobial Agents and Chemotherapy·Prajakta S BadriRajeev M Menon
Feb 13, 2019·Journal of Clinical Pharmacology·Scott R Penzak, Carlos Rojas-Fernandez
Aug 5, 2020·The Journal of Antimicrobial Chemotherapy·Catherine HodgeSaye Khoo
Feb 23, 2019·Frontiers in Pediatrics·Nathan John HananBrookie M Best
Jun 26, 2020·Journal of Clinical Medicine·Vincenzo RussoGerardo Nigro

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.